Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSunnybrook Health Sciences Centre

About this trial

Over 500 million people have been infected with COVID-19, and to date, more than 6 million people have died. Many individuals who have recovered from COVID-19 continue to experience symptoms even after they have been "cured" of the disease. This condition is known as post COVID-19 condition, which can have serious health consequences. A common symptom among these individuals is chronic fatigue, characterized by persistent tiredness or lack of energy. This study aims to explore a novel treatment for symptoms of post COVID-19 condition, known as hyperbaric oxygen therapy. This approach has shown promise in helping people with post COVID-19 conditions and treating some other causes of fatigue.

Hyperbaric oxygen therapy involves placing patients in a small chamber where they receive high oxygen gas levels. However, this treatment is expensive and time-consuming, and it is unclear if this treatment can be effectively assessed in a large-scale research study. This small study will help us decide if conducting a large research study is feasible. The investigators aim to assess if hyperbaric oxygen therapy can improve symptoms of post COVID-19 condition, such as fatigue.

Eligibility criteria

Qualifiers

Age ≥ 18 years old

Officially diagnosed with post COVID-19 condition by a healthcare practitioner

At least three months since SARS-CoV-2 infection

Difficulty thinking or problem solving ('brain fog')

Disqualifiers

Contraindications/medically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)

Patients with cognitive difficulties and/or mental retardation before COVID diagnosis

History of traumatic brain injury

Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)

Trial design

Treatments tested in this trial

  • Monoplace Hyperbaric Chamber (Class III medical device).

Treatment groups

40 Participants
are divided into 2 treatment groups